Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 20:42:108187.
doi: 10.1016/j.dib.2022.108187. eCollection 2022 Jun.

RNA-Seq data of ALKBH5 and FTO double knockout HEK293T human cells

Affiliations

RNA-Seq data of ALKBH5 and FTO double knockout HEK293T human cells

Egor A Smolin et al. Data Brief. .

Abstract

N6-methyladenosine (m6A) is the most abundant, highly dynamic mRNA modification that regulates mRNA splicing, stability, and translation. The m6A epigenetic mark is erased by RNA demethylases ALKBH5 (AlkB Homolog 5) and FTO (Fat mass and obesity-associated protein). The ALKBH5 and FTO RNA demethylases recognize m6A in similar nucleotide contexts. Therefore, these proteins can partially substitute for each other. To assess the impact of total m6A demethylation failure we performed high-throughput sequencing of cytoplasmic RNA from ALKBH5 and FTO double knockout and wild type HEK293T cells. The RNA-Seq libraries were sequenced on Illumina NextSeq 500, trimmed, and mapped to the human genome. The consequent read counting and differential expression analysis in the R environment detected 5871 differentially expressed and 166 alternatively spliced genes comparing double knockout against wild type HEK293T cells. Raw data are deposited in NCBI Gene Expression Omnibus (GEO) repository under GEO accession GSE198050.

Keywords: ALKBH5; Demethylase; Epitranscriptomics; FTO; RNA modifications; Transcriptome; m6A demethylation; m6A methylation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig 1
Fig. 1
Evaluation of ALKBH5 and FTO knockout. (A) Schematic representation of guide RNA (gRNA) locations. Two gRNAs targeting the third exon of FTO (for nickase CRISPR/Cas9) and two gRNAs targeting the first and third exons of ALKBH5 (for CRISPR/Cas9) are shown. The coordinates are according to the hg38 genome assembly. (B) Western blot of wild type and ΔALKBH5ΔFTO HEK293T cells using anti-ALKBH5, anti-FTO, and anti-ACTB as a loading control.
Fig 2
Fig. 2
The data are suitable for analysis of differential gene expression under FTO and ALKBH5 knockout. (A) Principal component analysis for three replicates of HEK293T (WT) and three double knockout (KO) samples, X and Y axes correspond to the first two principal components. (B) Barplot illustrating FTO and ALKBH5 expression in counts per million (CPM). (C) Volcano plot of differential expression analysis. The red line indicates 5% FDR, gray lines indicate -1 and 1 log2(Fold Change).
Fig 3
Fig. 3
The data are suitable for analysis of differential exon usage under FTO and ALKBH5 knockout. (A) Volcano plot of differential splicing analysis. The red line indicates 5% FDR, several illustrative examples of alternative splicing are highlighted. (B-F) Genomic views of RNA-Seq profiles for the selected genes with alternative splicing events.

Similar articles

Cited by

References

    1. He P.C., He C. m 6 A RNA methylation: from mechanisms to therapeutic potential. EMBO J. 2021;40 doi: 10.15252/embj.2020105977. - DOI - PMC - PubMed
    1. Bartosovic M., Molares H.C., Gregorova P., Hrossova D., Kudla G., Vanacova S. N6-methyladenosine demethylase FTO targets pre-mRNAs and regulates alternative splicing and 3’-end processing. Nucleic Acids Res. 2017;45:11356–11370. doi: 10.1093/nar/gkx778. - DOI - PMC - PubMed
    1. Wang J., Li Y., Wang P., Han G., Zhang T., Chang J., Yin R., Shan Y., Wen J., Xie X., Feng M., Wang Q., Hu J., Cheng Y., Zhang T., Li Y., Gao Z., Guo C., Wang J., Liang J., Cui M., Gao K., Chai J., Liu W., Cheng H., Li L., Zhou F., Liu L., Luo Y., Li S., Zhang H. Leukemogenic chromatin alterations promote AML leukemia stem cells via a KDM4C-ALKBH5-AXL signaling axis. Cell Stem Cell. 2020;27:81–97. doi: 10.1016/j.stem.2020.04.001. .e8. - DOI - PubMed
    1. Garcia-Campos M.A., Edelheit S., Toth U., Safra M., Shachar R., Viukov S., Winkler R., Nir R., Lasman L., Brandis A., Hanna J.H., Rossmanith W., Schwartz S. Deciphering the “m6A Code” via antibody-independent quantitative profiling. Cell. 2019;178:731–747. doi: 10.1016/j.cell.2019.06.013. .e16. - DOI - PubMed
    1. Zhang Z., Chen L.Q., Zhao Y.L., Yang C.G., Roundtree I.A., Zhang Z., Ren J., Xie W., He C., Luo G.Z. Single-base mapping of m 6 A by an antibody-independent method. Sci. Adv. 2019;5 doi: 10.1126/sciadv.aax0250. - DOI - PMC - PubMed